Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Cents and Sensibility - Kimberly and Friends' Consortium -- Ignore unavailable to you. Want to Upgrade?

To: Kimberly Lee who wrote (47548)	12/17/1999 4:45:00 PM
From: Tim Luke	Read Replies (1) \| Respond to of 108040

hi kim, i noticed all the tokyo blow people showing up stinking up your thread...consider it tainted now and move on....maybe you should set up your own site but you are wasting your talent here now...these guys are blood sucking leaches and they go from thread to thread.

To: Kimberly Lee who wrote (47548)	12/17/1999 4:59:00 PM
From: bobby is sleepless in seattle	Respond to of 108040

Kim...ewbx... early afternoon, also initiated at 40 1/2 with ewbx from a source who typically does not buy for momentum purposes...also, makr mentioned as a buy...

To: Kimberly Lee who wrote (47548)	12/17/1999 5:28:00 PM
From: nolimitz	Respond to of 108040

Thanks Kim. taking a vacation from the thread till things chill out. raising cash and mostly sitting on side lines. will check back in a few weeks or month. it was fun while it lasted. later all. nolimitz bookmark removed

To: Kimberly Lee who wrote (47548)	12/17/1999 7:15:00 PM
From: Mr Metals	Respond to of 108040

PennyProfiles- Stock hunters pennyprofiles.listbot.com .............working diligently for investors profits! CYGS .90 x .96 We're finally getting some investor awareness in regards to CYGS which is currently breaking it's recent high trading above the .90 range on good volume. The potential is setting in! The shareholders meeting confirmed that CYGS's ssDNA vector does work and the previous join venture with PCCA will be the preliminary means of marketing the technology. It was also confirmed that CYGS is indeed working on a licensing agreement with GENZYME GEN (NasdaqNM:GENZ) . CYGS also received some attention from CBS market watch several days ago. cbs.marketwatch.com, peaking some additional interest to a broader scope of investors. The company has much work ahead to complete their ultimate goal and is making good progress to that effect. I'll have a complete update as to any specifics when they become available and it's becoming more evident that CYGS is perusing through a specific marketing plan of their own ( with the joint venture with PCCA. We're extremely pleased with the companies prospects and progress. Good trading, Mic@PennyProfiles pennyprofiles.com Send your potential prospects to: mic@pennyprofiles. We've had some excellent ones as of late and will surly notify if we intend to profile your stock pick. DISCLAIMER: Penny Profiles makes no recommendations and encourages everyone to do their own due diligence!! We are not responsible for the results of your trading decisions. Nothing in this email shall constitute a solicitation or an offer to buy or sell any securities here in. All statements made are our own express opinion and should be treated as such. Everything contained in said email is for entertainment purposes only. There is never any need to merely rush into any stock ever mentioned through our e-mails.Penny Profiles is not compensated by any of the companies we mention. Trading in OTC stocks can be very risky and you can lose all or part of your money. All investment decisions should be discussed with a qualified investment professional.We are not liable for any losses or damages, monetary or otherwise, resulting from the use of our services. "Internet Fraud" is available on the SEC's Web site, at sec.gov. PLEASE EXERCISE CAUTION We honor all removals by simply responding to this e-mail and typing "remove" in the subject line.